The efficacy of Bacillus Calmette-Guerin (BCG) vaccination in protection against pulmonary tuberculosis (TB) is highly variable between populations. One possible explanation for this variability is increased exposure of certain populations to non-tuberculous mycobacteria (NTM). This study used a murine model to determine the effect that exposure to NTM after BCG vaccination had on the efficacy ...

In mice, the early host response to intravenous infection with small doses of dispersed Mycobacterium bovis BCG is controlled by the Bcg gene. After infection with a low dose of M. bovis BCG, Lyt-1+ cells were generated in the spleens of BCG-susceptible mice (Bcgs) in parallel with an increase in the proportion of phagocytic cells. Very few changes occurred in the splenic cell types of BCG-resi...

BACKGROUND Control of animal tuberculosis (TB) through vaccination has emerged as a long-term strategy to complement test and slaughter control strategy. A pilot trial under field conditions was conducted in a goat herd with high TB prevalence to assess the efficacy of the Mycobacterium bovis BCG vaccine. RESULTS Twenty-three goat kids vaccinated with BCG and other 22 unvaccinated control kid...

Bacillus Calmette-Guérin (BCG) is a vaccine used to prevent tuberculosis. It made from live, attenuated strain of Mycobacterium bovis . When injected into the human body, it causes mild infection that produces immunity tuberculosis bacterium. The BCG primarily as preventive measure against in children, and generates special resistance disease. To honor its inventors, French scientists Ca...

Background: The Expanded Program of Immunization (EPI) aims to increase immunization coverage. However, this cannot be achieved without an efficient data management system and ensuring quality. Objective: We aimed assess the quality at Sana’a capital. Methods: World Health Organization self-assessment tools were used. Three random urban districts only rural district (Bani-Al Hairth) capital sel...

Purpose. Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is indicated for high-grade nonmuscle-invasive bladder cancer (NMIBC). The efficacy of BCG in patients with a history of previous pelvic radiotherapy (RT) may be diminished. We evaluated the outcomes of radical cystectomy for BCG-treated recurrent bladder cancer in patients with a history of RT for prostate cancer (PC). Methods....

UNLABELLED Pathogenic and nonpathogenic species of bacteria and fungi release membrane vesicles (MV), containing proteins, polysaccharides, and lipids, into the extracellular milieu. Previously, we demonstrated that several mycobacterial species, including bacillus Calmette-Guerin (BCG) and Mycobacterium tuberculosis, release MV containing lipids and proteins that subvert host immune response i...

Nine of 355 cases of symtopmatic HIV-infected children who admitted to Chiang Mai University Hospital from January 1989 to December 1994 had complication due to BCG vaccination. The median age was 15 months with its range from 8 to 22 monts. Four cases presented with ulceration of the previously-healed BCG scar with ipsilateral enlarged and inflamed axillary nodes. Four cases had ipsilateral en...

Between 15 and 20% of patients with newly diagnosed urothelial cancer (UC) of the bladder will have high grade (HG) non-muscle invasive (NMI) disease including carcinoma-in-situ (CIS) and stage Ta and T1 tumors [1]. After transurethral resection of the cancer (TURBT), patients may undergo re-TURBT, but if no muscle invasive (MI) cancer is found most will receive an induction course of 6 weekly ...